Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study
The timing of administration of early antiviral therapy is crucial to reduce SARS-CoV-2 infection duration in immunocompromised patients and the combination with a mAb is associated with earlier viral clearance, as long asmAb is chosen among those effective against circulating variants.
Authors
- Mario Annunziata
- Alessia D’Agostino (ORCID: https://orcid.org/0000-0002-4309-1083)
- Salvatore di Bernardo
- Giulio Viceconte (ORCID: https://orcid.org/0000-0003-3989-2520)
- Letizia Cattaneo
- Antonio Riccardo Buonomo (ORCID: https://orcid.org/0000-0002-4378-8366)
- Francesco Grimaldi (ORCID: https://orcid.org/0000-0003-2286-5091)
- Ivan Gentile (ORCID: https://orcid.org/0000-0002-5199-8451)
- Emilia Trucillo
- Alessia Sardanelli
- Daria Pietroluongo
- Maria Foggia
Institutions
- Ospedale Antonio Cardarelli (IT)
- Fatebenefratelli Hospital (IT)
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1080/23744235.2025.2553664
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00